Paolo Tarantino (@ptarantinomd) 's Twitter Profile
Paolo Tarantino

@ptarantinomd

Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale. SoMe Editor @ESMO_Open. Interested in breast oncology, HER2, ADCs & good music.

ID: 958742483856486400

calendar_today31-01-2018 16:43:15

11,11K Tweet

24,24K Followers

600 Following

Paolo Tarantino (@ptarantinomd) 's Twitter Profile Photo

Results from DESTINY-CRC02 published in The Lancet Oncology. Among patients with pretreated, HER2+ mCRC, the lower dose of T-DXd (5.4 mg/kg) led to higher ORR and longer PFS than the higher dose (6.4 mg/kg), with nearly half the rate of ILD. Less can be more. thelancet.com/journals/lanon…

Results from DESTINY-CRC02 published in <a href="/TheLancetOncol/">The Lancet Oncology</a>. Among patients with pretreated, HER2+ mCRC, the lower dose of T-DXd (5.4 mg/kg) led to higher ORR and longer PFS than the higher dose (6.4 mg/kg), with nearly half the rate of ILD. Less can be more. thelancet.com/journals/lanon…